Solx Inc.
Reinvigorating a natural pathway to relieve intraocular pressure
This article was originally published in Start Up
Executive Summary
The gold standard for treating refractory glaucoma, trabeculectomy creates an artificial pathway to relieve intraocular pressure by forming an external bleb or blister under the eyelid so that aqueous humor fluid can drain from inside the eye to the bleb. Solx Inc. has developed an implantable device that improves on that method. The Solx Gold Shunt is a flat tube that detours fluid within the eye by using an existing pathway (the suprachoroidal space) that gradually shuts down as one ages. The shunt reconnects and reinvigorates this outflow pathway.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.